Clevudine: Phase III started

VRUS began the double-blind, international Phase III QUASH1 trial (Study 305) in 376 treatment-naïve, HbeAG+ HBV patients to compare 30 mg clevudine once daily vs. 10 mg adefovir once daily for 48 wee...